Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
NCT07228741 on ClinicalTrials.gov · last registry update 2026-06-04
A small phase 2 — 20 participants, against a typical 110. Due to report November 2027. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- St. Jude Children's Research Hospital
- Sponsor type
- Other
- Enrollment
- 20
- Started
- 2026-04-23
- Primary completion
- 2027-11 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise.
Conditions studied
Acute Lymphoblastic Leukemia · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.